Filtered By:
Condition: Epilepsy
Cancer: Brain Cancers
Therapy: Pain Management

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Why acupuncture is giving sceptics the needle
Acupuncture has been prescribed by half of Britain's doctors, but after 3,000 clinical trials its efficacy remains unproven. So is the NHS making a grave error in supporting this ancient treatment?• Are vitamin pills a sham? Q&A with Dr. Paul OffitYou can't get crystal healing on the NHS. The Department of Health doesn't fund faith healing. And most doctors believe magnets are best stuck on fridges, not patients. But ask for a treatment in which an expert examines your tongue, smells your skin and tries to unblock the flow of life force running through your body with needles and the NHS will be happy to oblige.The govern...
Source: Guardian Unlimited Science - July 26, 2013 Category: Science Authors: David Derbyshire Tags: Culture Health Science and scepticism Features NHS Alternative medicine The Observer Source Type: news

Pre-injury Comorbidities Are Associated With Functional Impairment and Post-concussive Symptoms at 3- and 6-Months After Mild Traumatic Brain Injury: A TRACK-TBI Study
Conclusions: Pre-injury psychiatric and pre-injury headache/migraine symptoms are risk factors for worse functional and post-concussive outcomes at 3- and 6-months post-mTBI. mTBI patients presenting to acute care should be evaluated for psychiatric and headache/migraine history, with lower thresholds for providing TBI education/resources, surveillance, and follow-up/referrals. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01565551. Introduction Traumatic brain injury (TBI) remains a significant cause of morbidity and mortality worldwide. In 2013 ~2.8 million TBI cases were recorded an...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news